Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol. 2019;74(10):e177-232.

Article  PubMed  PubMed Central  Google Scholar 

Group TASC. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.

Article  Google Scholar 

Cainzos-Achirica M, Miedema MD, McEvoy JW, Al Rifai M, Greenland P, Dardari Z, et al. Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019: the mesa study (Multi-Ethnic Study of Atherosclerosis). Circulation. 2020;141(19):1541–53.

Article  PubMed  PubMed Central  Google Scholar 

Dzaye O, Razavi AC, Dardari ZA, Nasir K, Matsushita K, Mok Y, et al. Carotid ultrasound‐based plaque score for the allocation of aspirin for the primary prevention of cardiovascular disease events: the multi‐ethnic study of atherosclerosis and the atherosclerosis risk in communities study. J Am Heart Assoc. 2024.

Lacaze P, Bakshi A, Riaz M, Polekhina G, Owen A, Bhatia HS, et al. Aspirin for primary prevention of cardiovascular events in relation to Lipoprotein(a) Genotypes. J Am Coll Cardiol. 2022;80(14):1287–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chasman DI, Shiffman D, Zee RYL, Louie JZ, Luke MM, Rowland CM, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203(2):371–6.  

Bhatia HS, Becker RC, Leibundgut G, Patel M, Lacaze P, Tonkin A, et al. Lipoprotein(a), platelet function and cardiovascular disease, Vol. 21. Nat Rev Cardiol. 2024.

Razavi AC, Richardson LTC, Coronado F, Dzaye O, Bhatia HS, Mehta A, et al. Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a). Am J Prev Cardiol. 2024;18:100674.

Article  PubMed  PubMed Central  Google Scholar 

Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. J Am Med Assoc. 2019;321(3):2245.

Article  Google Scholar 

Shiffman D, Chasman DI, Ballantyne CM, Nambi V, Devlin JJ, Boerwinkle E. Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study, Vol. 102. Thromb Haemos. 2009.

McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379(16):1499–508.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Visseren F, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, Vol. 42. Eur Heart J. 2021;42:3227–337.

Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, Coker TR, et al. Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement,  Vol. 327, JAMA. J Am Med Assoc. 2022.

Collins R, Peto R, Hennekens C, Doll R, Bubes V, Buring J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678).

Article  PubMed  Google Scholar 

Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11).

Article  CAS  PubMed  Google Scholar 

Tsimikas S. A test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies, Vol. 69. J AmColl Cardiol. 2017.

Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57(5).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem. 1991;266(4).

Article  CAS  PubMed  Google Scholar 

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. New Engl J Med. 2005;352(13).

Article  CAS  PubMed  Google Scholar 

Bhatia HS, Trainor P, Carlisle S, Tsai MY, Criqui MH, DeFilippis A, et al. Aspirin and cardiovascular risk in individuals with elevated Lipoprotein(a): the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2024;13(3):e033562.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27(9).

Article  CAS  PubMed  Google Scholar 

Shiffman D, O’Meara ES, Bare LA, Rowland CM, Louie JZ, Arellano AR, et al. Association of gene variants with incident myocardial infarction in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2008;28(1).

Article  CAS  PubMed  Google Scholar 

Morrison AC, Bare LA, Chambless LE, Ellis SG, Malloy M, Kane JP, et al. Prediction of coronary heart disease risk using a genetic risk score: The atherosclerosis risk in communities study. Am J Epidemiol. 2007;166(1).

McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. New Engl J Med. 2018;379(16).

Article  CAS  PubMed  Google Scholar 

Cui K, Yin D, Zhu C, Song W, Wang H, Jia L, et al. How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention? J Am Heart Assoc. 2022;11(9).

Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein ( a ) in clinical practice. J Clin Lipidol. 2024;1–12. https://doi.org/10.1016/j.jacl.2024.03.001